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Abstract
Aims/hypothesis The aim of this study was to reduce the
frequency of diabetic eye-screening visits, while maintaining
safety, by using information technology and individualised
risk assessment to determine screening intervals.
Methods A mathematical algorithm was created based on
epidemiological data on risk factors for diabetic retinopathy.
Through a website, www.risk.is, the algorithm receives
clinical data, including type and duration of diabetes,
HbA1c or mean blood glucose, blood pressure and the
presence and grade of retinopathy. These data are used to
calculate risk for sight-threatening retinopathy for each
individual’s worse eye over time. A risk margin is defined
and the algorithm recommends the screening interval for
each patient with standardised risk of developing sight-
threatening retinopathy (STR) within the screening interval.
We set the risk margin so that the same number of
patients develop STR within the screening interval with
either fixed annual screening or our individualised
screening system. The database for diabetic retinopathy
at the Department of Ophthalmology, Aarhus University
Hospital, Denmark, was used to empirically test the
efficacy of the algorithm. Clinical data exist for 5,199
patients for 20 years and this allows testing of the
algorithm in a prospective manner.
Results In the Danish diabetes database, the algorithm
recommends screening intervals ranging from 6 to
60 months with a mean of 29 months. This is 59% fewer
visits than with fixed annual screening. This amounts to 41
annual visits per 100 patients.
Conclusion Information technology based on epidemio-
logical data may facilitate individualised determination of
screening intervals for diabetic eye disease. Empirical
testing suggests that this approach may be less expensive
than conventional annual screening, while not compro-
mising safety. The algorithm determines individual risk
and the screening interval is individually determined
based on each person’s risk profile. The algorithm has
potential to save on healthcare resources and patients’
working hours by reducing the number of screening
visits for an ever increasing number of diabetic patients
in the world.
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Introduction
From a public health standpoint, screening for diabetic eye
disease is one of the most cost effective preventative health
procedures available [1–3]. Annual examinations are
standard in most diabetic eye-screening programmes and
recommended by the World Health Organization and most
health authorities and organisations involved in diabetes
and ophthalmology [4–6]. As the prevalence of diabetes
mellitus worldwide is rising and with it the total cost of
screening, it becomes more important to make screening
programmes as effective as possible [7].
With a fixed interval between screening visits, the
interval is the same for all, whereas the risk of developing
sight-threatening retinopathy (STR) between screening
visits is individually variable. Some patients are at high
risk of developing STR and requiring treatment before the
next screening visit, whereas for others this risk would be
low. The fixed screening interval must be geared towards
patients at relatively high risk; otherwise they might go
blind. The fixed ‘one size fits all’ approach to screening
leaves room for improvement. By basing the screening
interval on each patient’s risk margin, it should be
possible to increase screening frequency for those at high
risk and thereby increase their safety and at the same time
reduce the screening frequency for patients at low risk and
reduce expenditure on healthcare costs and patients’ time
(Fig. 1). Indeed, such an approach might apply to a variety
of diseases.
In 1991 Dasbach and associates examined various
approaches to screening for diabetic retinopathy [8]. In
1993, Kalm and Jonsson [9] proposed variable screening
intervals based on risk margins and in 1994 the Icelandic
screening programme moved in this direction by lengthening
the screening interval to 2 years for diabetic patients without
retinopathy [10]. This approach has proven to be safe and
effective [11], and has been adopted by many diabetic eye-
screening programmes. Classifying risk margins based on
broad classification, such as presence or absence of
retinopathy, is easily mastered by the busy clinician and is
traditional in medicine. This approach can be improved
dramatically by taking into account more risk factors in a
quantitative way with the help of information technology.
The risk factors for incidence and progression of diabetic
retinopathy are well known and include duration and type
of diabetes, mean blood glucose or HbA1c, systolic blood
pressure, and presence of retinopathy [12–18]. On the basis
of these risk factors it is possible to calculate the individual
risk for the development and progression of diabetic
retinopathy. While a quantitative calculation based on five
or six variables cannot easily be made by the busy clinician,
a mathematical algorithm in a computer can do so in
seconds. The individual risk for progression to sight-
threatening retinopathy (STR) is a sound foundation for
recommending an appropriate screening interval for the
individual patient, where the risk margin for developing
STR (diabetic macular oedema or proliferative diabetic
retinopathy) within the screening interval is pre-determined.
In this study we use a mathematical algorithm based on
known risk factors to obtain an individualised risk
assessment, which is used to determine screening intervals
for diabetic retinopathy. The purpose is to standardise
individual risk, use the risk assessment to control screening
intervals and make screening programmes more effective.
Fig. 1 The schematic drawings illustrate the conceptual difference
between fixed annual screening and the individualised approach to
diabetic eye screening. a Annual screening: the group of diabetic
patients with variable risk for sight-threatening diabetic retinopathy.
Red indicates high risk, yellow, medium and green, low risk. All have
fixed 12 month screening intervals. However, their risk of developing
sight-threatening diabetic retinopathy within the year is vastly
different. This is the ‘one size fits all’ approach. b The individualised
screening: again the group of diabetic patients with variable risk is
depicted. Here the screening interval is based on the individual risk.
Patients at high risk are screened more frequently, up to every
6 months, whereas patients at low risk are screened less frequently,
down to every 5 years
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Methods
A mathematical algorithm to compute the risk of STR was
created based on: (1) epidemiological data for the prevalence
of diabetic retinopathy from the Icelandic eye-screening
database [18–21]; and (2) on risk factors from published
reports [12–17] (Table 1). Individual or personal data was
not considered in the creation of the algorithm, whereas
individual data from the Aarhus diabetic database was
used in the empirical testing (see below).
The risk function was based on the Weibull proportional
hazards model. The model has two parts: (1) the baseline
cumulative probability of STR; and (2) the relative risks
associated with risk factors. It is a standard parametric survival
function and has, for example, been used in the SCORE
project of the European Society of Cardiology to estimate
cardiovascular risk [22]. From this model the baseline
survival probability for being free of disease, that is, STR,
has the form S0(t)=exp[−exp(α) tp], where t is the time from
onset (duration) of diabetes and exp() is the exponential
function. The values of α and p define the shape of the
survival function and provide flexibility to accurately
describe collected survival data. The baseline survival
probability of STR is 1 minus the probability of being free
of STR or F0ðtÞ ¼ 1 S0ðtÞ ¼ 1 exp exp að Þtp½ .
The variables α and p, to define S0(t), were found
separately for type 1 and type 2 diabetes by fitting F0(t) to
epidemiological data on STR in Iceland [18–21]. The
nlminb optimisation routine in R, for non-linear curve
estimation, was used for fitting of F0(t) with results
displayed in Fig. 2 [23]. For type 1 diabetes we found that
F0ðtÞ ¼ 1 exp exp 7:849ð Þt2:075½  and for type 2 we
found that F0ðtÞ ¼ 1 exp exp 4:88½ t1:170ð Þ  0:052½ .
For type 2 we used an offset of 0.052 in risk because it was
estimated that 5.2% of newly diagnosed participants had
already developed STR [18].
Proportional hazards were assumed, as is typical for risk
models and was assumed in the analysis of the UK Prospective
Diabetes Study (UKPDS) and Wisconsin data [12–14, 17], to
generate personalised estimates of ‘survival’ free from STR
by exponentiating S0(t) with a linear combination of
established risk factors and relative risk variables so that the
individual survival was S(t)=S0(t)
exp(linear combination). For type
1 diabetes the linear combination used had the form:
HbA1c %½   8ð Þ  0:1851þ sbp 130ð Þ  0:007813
þ DRpresent 0:52ð Þ  1:1þ bDRð Þ
where βDR=0.194 for men and βDR=−0.194 for women
when DR is present and βDR=0 otherwise. Here sbp stands
for systolic blood pressure and DRpresent=1 if diabetic
retinopathy was present and DRpresent=0 otherwise. For
type 2 diabetes, the linear combination was
HbA1c %½   8ð Þ  0:380544þ sbp 130ð Þ  0:04308
þ DRpresent 0:33ð Þ  0:89þ bDRð Þ;
where βDR=0.46 for men and βDR=−0.46 for women if
diabetic retinopathy was present and βDR=0 otherwise. The
linear combination was centred on mean values of HbA1c and
systolic blood pressure in the Icelandic diabetic population,
namely 8% (64 mmol/mol) and 130 mmHg respectively, and
the prevalence of diabetic retinopathy for type 1 diabetes was
52%, and for type 2 diabetes was 33%. This was done to
calibrate the risk so that F0(t) defined the average risk in the
population.
The risk of developing STR in a time interval Δt, for a
retinopathy free individual with given risk factor values and t
as the duration of diabetes at time t, was then computed as:
risk Δtjdisease free at tð Þ ¼ 1 S t þΔtð Þ=SðtÞ
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Fig. 2 Prevalence of STR by duration of diabetes. Prevalence data
from the Icelandic diabetic population (dashed line/circles) with fitted
Weibull cumulative probability curve (solid line). a Prevalence for
type 1 diabetes. b Prevalence for type 2 diabetes
Table 1 Major risk factors and their risk ratios for progression of
diabetic retinopathy used in our project, and citations for relevant
epidemiological studies
Variable Risk
ratio
95% CI Reference
Type 1 diabetes
HbA1c (%) 1.20 1.16, 1.25 [14]
Systolic BP (10 mmHg) 1.08 1.04, 1.12 [14]
NPDR
Female 2.74 NA [14, 15]
Male 3.30 NA [14, 15]
Type 2 diabetes
HbA1c (%) 1.46 1.05, 2.02 [13]
Systolic BP (10 mmHg) 1.54 1.06, 2.27 [12]
NPDR
Female 1.78 NA [15, 16]
Male 3.30 NA [15, 16]
NPDR, nonproliferative diabetic retinopathy
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To compute the time interval Δt when the risk would
reach a value r, between 0 and 1, the equation:
risk Δtjdisease free at tð Þ ¼ r
was solved for Δt. The solution Δt was then used as the
recommended maximum screening time for the patient
before the risk would reach the risk margin, r.
Through a website, www.risk.is, the algorithm receives
clinical data including type and duration of diabetes, HbA1c
or mean blood glucose, blood pressure and the presence
and grade of retinopathy (see electronic supplementary
material [ESM] Fig. 1). These data are used to calculate risk
for STR for each individual’s worse eye over a given time
span. An acceptable risk margin is defined and the algorithm
recommends the screening interval for each patient, i.e. when
(s)he should next be seen in the screening clinic. For
empirical testing the risk margin was set so that the number
of individuals with STR at the next screening visit was equal
with our algorithm and fixed annual screening. In the Aarhus
database 149 patients out of 5,199 developed STR during
their first year in the screening programme. This amounts to
2.9% and the risk margin in our algorithm was set at 3.2% to
match this rate. The risk margin is slightly higher because of
the difference in mean risk between the Aarhus data and the
Icelandic population data.
Empirical testing for safety and efficacy of the algorithm
was performed using patient records in the database for
diabetic retinopathy at the Department of Ophthalmology,
Aarhus University Hospital, Denmark. The database is
described in detail by Mehlsen et al. [24, 25]. Prospectively
accumulated clinical data, fundus photographs and infor-
mation on outcome are available for 5,199 patients over
20 years and this allows testing of the algorithm in a
prospective manner.
Receiver operating characteristics (ROC) analysis of the
diagnostic capacity of the algorithm was performed using
the roc package in the statistical program R [23].
For each patient in the database the risk of STR was
calculated at the first recorded visit in the database. This
risk level was used to determine the recommended
screening interval, Δt, for the first interval alone. The
clinical outcome as recorded in the database was used to
empirically find whether each individual patient developed
STR within the recommended interval.
Missing values in the Aarhus database were handled as
follows: missing blood pressure values were set at 130 mmHg
and HbA1c at 8% (64 mmol/mol). There were missing values
for blood pressure for a total of 3,492 patients (67%) out of
5,199 patients. There were missing values for HbA1c for
1,131 patients (22%) out of 5,199 patients. Individual data
for duration of diabetes, sex, and presence of diabetic
retinopathy or STR were available for all patients.
For clinical use it was decided to impose a 6 month floor
and 60 month ceiling to screening intervals.
Results
Testing the algorithm in the Aarhus diabetic database
indicates that the mean recommended screening interval is
29 months. The reduction in screening frequency is 59%
compared with fixed annual screening; 2.9% of the patients
developed STR before the next screening visit.
ESM Fig. 1 shows a computer screen shot and an
example of how the algorithm is used for an individual
patient. The patient’s clinical data are entered in the panel
and the graph shows this patient’s risk of developing STR
over time. The algorithm recommends that this patient be
screened again after 24 months, as is shown in red on the
computer screen.
Figure 3 shows the recommended screening interval for
type 1 and 2 diabetes patients with variable risk profiles as
determined by their risk factors. The screening interval is
limited by the 6 month floor and 60 month ceiling and
varies according to individual risk. The risk profiles for
individual diabetic patients are highly variable. The mean
screening interval is 29 months and the median is
23 months. The first quartile for the screening interval is
11 months and the third quartile is 49 months.
Figure 4a shows a ROC curve, and the area under the
curve was found to be 0.76 (95% CI 0.74, 0.78). This
number indicates that there is a 76% probability that a
randomly selected patient who develops STR will be given
a higher risk score than a randomly selected patient who
does not develop STR. Figure 4b shows a calibration graph,
showing the observed fraction of STR events within each
decile of estimated risk.
Discussion
This is the first report to present a mathematical algorithm,
based on epidemiological data on risk factors for diabetic
retinopathy, to determine screening intervals for diabetic
eye disease. Empirical testing in the Danish database
suggests that this approach gets the same results with fewer
screening examinations than the fixed annual screening
programmes currently in use. With the standard risk margin
the number of screening visits is reduced by 59% compared
with annual screening, with the same number of patients
developing STR before the next screening visit. This
reduces the cost for screening programmes and improves
utilisation of healthcare resources.
Regular screening and preventive treatment for diabetic
retinopathy is a powerful tool to reduce blindness. In
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Fig. 3 Screening time (months)
by type of diabetes, HbA1c,
systolic blood pressure, diabetic
retinopathy (DR; including
proliferative retinopathy [PDR])
and sex. The figure shows the
recommended screening interval
for patients with variable risk
profiles as determined by their
risk factors. A 6 month floor and
a 60 month ceiling is applied
and the screening interval ranges
from 6 months in high-risk
individuals to 5 years for those
at low risk. Recommended
screening intervals are shown in
(a) for type 1 diabetes patients
and in (b) for type 2 diabetes
patients. Red, ≤6 months;
orange, 7–12 months; yellow,
13–24 months; light green,
25–36 months; dark green, 37–
48 months; blue, ≥49 months.
To convert values for HbA1c in
% to mmol/mol, subtract 2.15
and multiply by 10.929
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Iceland, the prevalence of blindness within the diabetic
population decreased from 2.4% to 0.5% following the
onset of screening in 1980, and this is largely attributable to
the public health programme [2, 10, 18–21, 26]. Compa-
rable success has been seen with similar programmes in
Sweden and Denmark [27–29].
The list of risk factors includes type and duration of
diabetes, HbA1c, systolic blood pressure, sex, and the
presence and grade of retinopathy. These factors have been
reported to predict the development of retinopathy (Table 1).
It is an advantage that the algorithm uses only a few risk
factors, which makes it easy to use for the patient or the
clinician. Mean blood glucose is the number that appears on
the blood sugar meter when turned on and could be used as
a substitute for HbA1c in cases where the HbA1c is
unknown by the patient. Using a mean weighted HbA1c
would be a better and a more accurate way of estimating
blood sugar control than using HbA1c at a single point in
time, since these values are not constant for an individual
patient. In practice we would recommend that physicians
calculate a mean of the last three HbA1c measurements for
each individual patient to give a recommendation on the
screening interval. If an individual patient has HbA1c
measurements in a wide range it would also be recom-
mended to go with the worst case scenario and use the
highest HbA1c level.
For example, a male patient with type 2 diabetes with
duration of 10 years, blood pressure of 130/80 mmHg
and no known retinopathy would have a screening
interval of 53 months with HbA1c of 7% (53 mmol/
mol). This would change to 17 months if HbA1c increased
to 10% (86 mmol/mol). For a similar patient with 20 year
duration of diabetes, the recommended screening interval
would be 47 months with HbA1c of 7% (53 mmol/mol)
and only 15 months with HbA1c of 10% (86 mmol/mol).
We expect that each diabetic patient be followed up on a
regular basis by his diabetologist or general practitioner.
Should the patient’s risk factors change over time, the risk
analysis and recommendation for the screening interval
should be adjusted.
Gross proteinuria is a risk indicator of proliferative
diabetic retinopathy in younger-onset patients but the
relationship was of borderline statistical significance in a
population-based study in Wisconsin [30]. Proteinuria may
not be strongly predictive for the development of retinop-
athy and we do not use proteinuria as a predictor in our
algorithm. Somewhat counter-intuitively, smoking status
was inversely related to the development of new lesions
and progression of established retinopathy in the UKPDS50
study [16]. In spite of this data we opted not to include
smoking in the risk calculator due to the deleterious effects
of smoking in terms of cardiovascular and lung cancer risk
that would far outweigh the retinopathy risk reduction in
terms of total morbidity.
This study can be seen as an extension of our earlier
studies [10, 11], which show that alternate year screening
for diabetic eye disease seems to be safe and effective in
diabetic patients without retinopathy and, by doing this, the
financial savings are substantial. In this study we have gone
further and used information technology and available
epidemiological studies to standardise the risk and make
individual determinations of screening intervals for diabetic
eye disease. This makes screening programmes more
focused and less expensive. In the early days of diabetic
eye screening, Dasbach [8] suggested that cost effectiveness
of screening could be improved by selectively targeting
high-risk groups of the diabetic population. This was
followed by the work of Kalm and Jonsson [9], who also
used modelling work to suggest that diabetic screening
intervals could be varied and lengthened based on the risk
profile of diabetic patients.
We face a global epidemic of diabetes [31, 32], where
the number of patients with diabetes in the world is
estimated to increase from 171 million in 2000 to at least
366 million in 2030 [7]. While public health programmes
for diabetic eye screening are very effective and indeed
highly cost effective [1], they are expensive to operate,
owing to the very large number of patients. The cost per
screening visit in the ophthalmologist-based Icelandic
screening system is approximately 53 euros, and the cost
involved in photographic screening programmes in Europe
is 30–40 euros. Let us assume that each screening visit in
developed countries costs 40 euros and the visit and travel
takes 2 working hours of the patient’ time. Annual
screening for 1 million diabetic patients would cost 40
million euros and 2 million working hours and this cost
could be reduced by 59% with our algorithm. Wild et al.
[7], estimate the prevalence of diabetes in the USA to be 18
million in 2000 and 30 million in 2030 and it is reasonable to
assume that Europe’s somewhat larger population is similar,
and we will estimate the current number at 25 million
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Fig. 4 a ROC curve, with area under the curve of 0.76 (95% CI 0.74,
0.78). b Calibration graph, showing observed fraction of STR events
within each decile of estimated risk. The error bars represent 95% CI
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diabetic patients in each region. In this case, either Europe or
the USAwould each require about 1 billion euros and 50
million working hours annually to conduct a fixed annual
diabetic eye-screening programme. Individualised risk
assessment and screening in Europe or the USA could save
580 million euros and 29 million working hours each year in
each region. In both cases the benefit of reduced prevalence
of blindness would far outweigh the cost of screening [1].
Our algorithm is based on large international studies on
diabetic retinopathy [12–18], and published literature on the
epidemiology of diabetic retinopathy was considered. Our
algorithm is based on the Icelandic population and it was
tested empirically in a Danish population. Both are white
with Nordic heritage. While this gives us reasonable
confidence in our conclusion, further testing in other
populations would be valuable, particularly in order to
extend these results to populations of different ethnicity.
The Aarhus database represents prospectively accumu-
lated data of diabetic patients over 20 years. This database
allows empirical testing of the outcome for the algorithm
based on actual data from actual patients with recorded data
at reported time points. A large prospective study is
desirable for further testing of our protocol.
The distribution of screening intervals is shown in Fig. 3.
Here, the 6 month floor and 60 month ceiling is applied,
which removes the extremes in screening intervals.
The area under the ROC curve in Fig. 4a was 0.76, which
represents an acceptable diagnostic capacity and is within the
range typical for risk models for cardiovascular disease [33].
Figure 4b demonstrates that the algorithm tends to
overestimate the risk, especially for high risk. This may
be due to a number of factors. In our algorithm we assume
that the risk factors are independent, which may not be
exact. Also, we assume that the risk factors have a linear
effect over the entire range, which may not apply for high
values. Third, some of the patients with high-risk character-
istics may have received treatment to improve the risk
factors such as blood glucose and blood pressure. Fourth, in
a relatively large group of patients, default values had to be
applied for blood pressure and this could also be respon-
sible for some errors. And last, the baseline cumulative
prevalence in our data may not be directly transferable to a
new population. Simple calibration methods, such as
suggested by van Houwelingen [34], could be applied to
the risk function to refine the adaptation to the population
using the algorithm. The observed fraction of STR events
by deciles of risk would then be seen to be closer to the
diagonal in Fig. 4b. This has no effect on risk ranking in the
database and therefore the diagnostic capacity of the
algorithm stays the same.
Eye screening and preventive treatment for the 200–300
million diabetic patients in the world would substantially
decrease the global burden of blindness [1–3]. Such
screening is still a distant dream, in spite of 20 years of
goals and plans by major medical organisations. One reason
for the lack of success is the considerable cost of such a
programme and the lack of resources, both money and
manpower. Our information technology can decrease the
costs by more than half and help make global diabetic eye
screening economically feasible. The basic approach used
in this project could be applied to other disease categories
and healthcare delivery. Information technology based on
available epidemiological data opens the way to individu-
alised allocation of healthcare resources, which will make
healthcare more economical and more effective in general.
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